NCT04853342View on ClinicalTrials.gov

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

PHASE3RecruitingINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2030

Conditions
Non-small Cell Lung Carcinoma
Interventions
DRUG

Drug: Furmonertinib 80 mg

The initial dose of Furmonertinib 80 mg once daily

DRUG

Furmonertinib 80 mg placebo

The initial dose of Furmonertinib 80 mg once daily

Trial Locations (1)

215000

RECRUITING

First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY

NCT04853342 - To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | Biotech Hunter | Biotech Hunter